All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

An expert panel hosted by

The Lymphoma Hub logo and the Multiple Myeloma Hub logo

Sequencing immune-based therapies in B-cell malignancies

with Ulric Jäger, Sagar Lonial, and Krina Patel

Saturday, June 15 | 18:00-19:30 CEST

Register now

This independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.


The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

Dual antigen targeting immunotherapies in MM

May 7, 2024
Learning objective: After reading this article, learners will be able to cite a new clinical development in multiple myeloma.

Bookmark this article

Immune-based therapies in multiple myeloma (MM) include agents such as chimeric antigen receptor (CAR) T cells, as well as bispecific antibody therapies. These novel agents are often associated with high initial response rates compared with standard therapies, yet most patients go on to experience a relapse. In an effort to improve duration of response, dual antigen targeting and trispecific antibodies are currently being investigated in MM.1

Here we summarize a presentation by Sham Mailankody1 from the International Myeloma Society’s 5th Immune Effector Cell Therapies in Multiple Myeloma Workshop, 2024, on antigen-targeting CAR T cells and antibody therapies in MM.

Dual antigen-targeting1

  • The high incidence of relapse after immune therapies can be attributed to a multitude of resistance mechanisms; most commonly reduction or loss of the target antigen.
  • Immune therapies such as CAR T cells and bispecific antibodies are often administered sequentially after relapse. However, use of these therapies in combination to target more than one antigen simultaneously could be applied to further reduce malignant cells and extend duration of response.
  • In a mouse model, dual targeting of B-cell maturation antigen (BCMA) and G protein-coupled receptor class C group 5 member D (GPRC5D) resulted in a more durable response than either monotherapy in isolation.
  • Dual antigen targeting can be achieved using combinations of CAR T-cell and bispecific antibody therapies (Figure 1).

Figure 1. Methods of dual antigen-targeting in MM* 

CAR, chimeric antigen receptor; TCE, T-cell engager.
Created with
*Adapted from Mailankody.1


  • RedirecTT-1 (NCT04586426) is a phase I/II clinical trial investigating the combination of teclistamab and talquetamab to simultaneously target BCMA and GPRC5D for the treatment of relapsed/refractory MM.
    • The trial design and latest data from RedirecTT-1 have been reported by the Multiple Myeloma Hub here.
  • Data collected from this trial provide evidence to support dual antigen targeting as a strategy to aid improve response rates, particularly in difficult-to-treat presentations such as extramedullary disease (EMD) (Figure 2).

Figure 2. Response rates from RedirecTT-1 in A response-evaluable patients and B patients with EMD* 

CR, complete response; PR, partial response; Q2W, once every 2 weeks; sCR, stringent complete response; tal, talquetamab; tec, teclistamab; VGPR, very good partial response.
*Adapted from Mailankody.1

Key learnings1

  • Preclinical data and early clinical trials suggest that dual antigen targeting could help to overcome resistance mechanisms to immune therapies.
  • More research is required in the clinical setting to establish whether dual antigen targeting results in increased response rates and, most importantly, increased response duration.

  1. Mailankody S. Dual antigen-targeted CAR T cells and trispecific antibodies. 2024 International Myeloma Society 5th Immune Effector Cell Therapies in Multiple Myeloma Workshop. Mar 23, 2024; Boston, US.


Subscribe to get the best content related to multiple myeloma delivered to your inbox